讲者：Georgina V. Long  澳大利亚

标题：Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial

中文标题：围手术期度伐利尤单抗联合或不联合替西木单抗加新辅助维恩妥尤单抗治疗肌层浸润性膀胱癌：Ⅲ期VOLGA试验结果

讲者：Thomas B. Powles  英国

标题：Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

中文标题：塔拉妥单抗联合度伐利尤单抗（durva）对比度伐利尤单抗作为广泛期小细胞肺癌（ES-SCLC）在度伐利尤单抗+铂类+依托泊苷（1L durva + EP）后一线维持（1LM）治疗：Ⅲ期DeLLphi-305试验主要分析

讲者：Jacob Sands 美国

标题：Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)

中文标题：达罗他胺联合雄激素剥夺治疗（ADT）及根治性或挽救性局部放疗（RT）治疗局限性极高危前列腺癌：一项国际、安慰剂对照、随机Ⅲ期试验（DASL-HiCaP；ANZUP1801）的中期分析

讲者：Tamim Niazi  加拿大 

标题：Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC

中文标题：Krascendo 1——divarasib（diva）对比索托拉西布（soto）或阿达格拉西布（ada）治疗既往经治的局部晚期或转移性KRAS G12C突变NSCLC的疗效和安全性

讲者：Ferdinandos Skoulidis 美国

标题：Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results

中文标题：奥希替尼（osi）联合赛沃替尼（savo）对比铂类–培美曲塞（plat–pem）治疗奥希替尼后EGFR突变伴MET过表达（OE）和/或扩增（AMP）的晚期NSCLC：SAFFRON III期（Ph 3）主要结果

讲者：陆舜 上海交通大学医学院附属胸科医院

标题：CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)

中文标题：CLARITY-Gastric 01（CG-01）：sonesitatug vedotin（Sone-Ve）用于二线或后线（2L+）晚期或转移性Claudin 18.2（CLDN18.2）阳性胃食管癌（GEC）的Ⅲ期研究

讲者：徐瑞华 中山大学肿瘤防治中心